Objective: Botulinum toxin type A (Botox) injection has been used to manage pain. However, it remains to be proved whether Botox injection is effective to relieve residual limb pain (RLP) and phantom limb pain (PLP).
clinical study. In this study, using both subjective and objective measurements, we piloted a prospective doubleblinded randomized pilot study to examine the effectiveness of Botox injection, and to compare its effectiveness to Lidocaine combined with Depomedrol injection on RLP and PLP in amputees who failed in conventional treatments.
METHODS
This study was performed as a prospective, doubleblind, randomized pilot study. The study protocol was reviewed and approved by the Institutional Review Board at Medical College of Wisconsin and all investigators completed training in both human research and patient privacy. All participants were informed about the study procedure and consented to participate.
Patient Selection
The participants were recruited from the Department of Physical Medicine and Rehabilitation at Medical College of Wisconsin, Milwaukee, WI. The enrollment period began in December, 2005 and lasted until December, 2007. Inclusion criteria were adult lower extremity amputees (18 or more years old) with clinical diagnosis of daily RLP and/or PLP greater than 5/10 on visual analog score (VAS) that were interfering with their prosthetic use, activities of daily living, and/or sleep and mood. All study amputees are single amputees who failed in conventional treatments, including oral medications, local anesthetic injections, and physical modalities such as massage, biofeedback, transcutaneous electrical stimulation, and desensitization therapy. Exclusion criteria were a previous history of Botox injections, bleeding disorder, myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, allergy or sensitivity to Botox, and ischemic distal residual limb; signs and symptoms of infection at the injection site or systemic infection; and evidence of pregnancy during the study. Sixteen participants were initially screened for this study. One participant was excluded due to the previous history of Botox injection, and another one was not eligible because of history of myasthenia gravis. Fourteen participants who qualified our inclusion criteria were included in this study.
Study Procedures
All eligible patients were randomly assigned to receive either Botox injection or Lidocaine/Depomedrol injection. One physician was chosen to implement the protocol treatment for all patients after the randomization. However, patients and evaluators (who were not the treating physician) were blinded to the type of treatment that was prescribed to the patient.
Focal tender points of RLP were first identified and marked on the residual limb during the physical examination. Then photographs of the residual limb were obtained. The pain tolerance (the maximum tolerable pressure) was measured using an algometer (Wegner instruments). The pressure pain tolerance was determined by using a handheld pressure algometer (Wegner instruments) with a circular probe area of 1 cm 2 . When pressure pain tolerance was reached, the evaluator froze the digital display immediately upon receiving the patient's report. Each value was determined 3 times and then averaged. Each patient received intramuscular and cutaneous/subcutaneous injection of Botox or Lidocaine/Depomedrol as detailed below.
Each patient was evaluated at 0 (immediately before injection), 1, 2, 3, 4, 5, and 6 months after the injection. Each evaluation included history and physical examination by 1 treating physician who delivered the protocol treatment to all patients, but was blinded for data collection and analysis. Others included the completion of the clinic follow-up form, measurement of algometry pain tolerance and VAS pain scale, prosthetic form, postinjection patient log, review of the patient's pain log form, and the pain level after the injections. These were performed and collected by our evaluator, a research associate or resident physician who was previously trained, and was blind to the type of treatment this patient received.
Medications
Clostridium Botulinum type A neurotoxin (Botox) from Allergan was used for this study. Botox was reconstituted with 0.9% normal saline to a concentration of 50 units/mL. An injection dosage of 1 mL, equal to 50 units of Botox was used for each injection site, with total units ranging from 250 to 300 units. Lidocaine/Depomedrol injection: 1% lidocaine (AstraZeneca LP) and 40 mg/mL of DepoMedrol (methylprednisolone acetate Injectable Suspension, Pharmacia & Upjohn Co) were used. A total amount of 1 mL mixture of 0.75 mL of 1% lidocaine and 0.25 mL of Depomedrol 40 mg/mL (10 mg) was injected into each painful site on the residual limb. Maximal of 6 painful sites were injected for each patient in both groups.
In our study, Botox or Lidocaine/Depomedrol was injected into both muscular and nonmuscular structures such as cutaneous/subcutaneous tissues and neuroma in addition to muscles under the electromyography guidance since all of our patients had muscle tightness with focal muscle fasciculation, focal tenderness, and/or neuroma formation. The tender spots at residual limb were identified and marked. Neither were pain medications adjusted, nor were other interventions provided during the study period.
Outcome Measurements
The primary outcome measurements included changes of intensity of RLP and PLP as recorded by VAS, and the changes of the pressure pain tolerance as determined by a pressure algometer.
Statistical Analysis
Mixed effects modeling with patient-specific random effects for RLP and PLP, and additional within-patient location random effects for pain tolerance was used for statistical analysis. The time trend in the outcomes was modeled as an immediate change due to the treatment followed by a linear trend afterwards. The model was fitted to both groups simultaneously to obtain more precise variability estimates, however, the effect of the 2 treatments was allowed to differ. The scores of VAS and pain tolerance were averaged over the points within a person when reporting averages, but not during analysis. The analyses were performed using SAS 9.2 (SAS Institute, Cary, NC). Due to the small sample size, which limits the power, and preliminary nature of this study, we reported differences significant at a 10% level.
Botox group dropped at 14 weeks owing to a vascular revision surgery in another limb. Another patient in the Botox group failed to follow-up in the 5-month visit after injection because of psychological exacerbation unrelated to his RLP and PLP. One patient in Lidocaine/Depomedrol did not complete the evaluation at the 6-month visit owing to noncompliance. Table 2 shows the summary statistics of changes from baseline in the 2 groups. Data analysis showed that both Botox and Lidocaine/Depomedrol injections resulted in immediate improvements (at 1-month follow-up) of RLP (Botox: P=0.002; Lidocaine/Depomedrol: 0.06) and the pain tolerance (Botox: P=0.01; Lidocaine/Depomedrol: P=0.07). The treatment effect lasted for 6 months after the treatment in each group, respectively (Figs. 1, 2) , with no evidence of a time trend (P=0.59 and P=0.96, respectively). Amputees randomized to receive Botox injection had higher starting pain (lower score in the pain tolerance) than those randomized to receive Lidocaine/Depomedrol injection (P=0.07) (Fig. 2) . These analyses are summarized in Table 3 . Visit-specific comparison analysis showed that the degree of RLP improvement was similar in the initial time points of visit (at 1 to 2 mo) between these 2 treatment groups, with higher effect size in the patients treated with Botox injection than Lidocaine/Depomedrol at the time points of visit (at 3 to 5 mo), and then became similar at the last time point of visit (at 6 mo) ( Fig. 1 ). However, there was no statistical difference in pain tolerance between these 2 groups (Fig. 2 ). In addition, no immediate improvement of PLP was observed after Botox or Lidocaine/Depomedrol injection (Botox: P=0.49; Lidocaine/Depomedrol: P=0.42) ( Fig. 3) . Similarly there is no posttreatment trend effect in either group for VAS-PLP (Botox: P=0.90; Lidocaine/Depomedrol: 0.18).
DISCUSSION
RLP and PLP are common painful conditions in amputees. The management of these types of pain is often difficult and challenging. Current treatments have failed to provide effective pain relief owing to either unresponsiveness or short lasting effect of pain reduction. 2, [5] [6] [7] [8] Lidocaine is a well-known anesthetic used for all kinds of local injections. It is effective but short-lived. Steroid injection has been routinely used for treatment of Morton neuroma, 12 and was recently reported for the treatment of a painful stump neuroma. 11 Corticosteroid, including Depomedrol combined with the local anesthetic agent such as lidocaine may extend the effect of pain relief through additional anti-inflammatory mechanisms in many painful conditions. [25] [26] [27] This is because Depomedrol as an antiinflammatory agent might inhibit the inflammatory process by limiting the capillary dilatation and permeability of vascular structures present in the mechanism of RLP. [25] [26] [27] The length of the treatment effect has been reported to vary from weeks to months. 10, 11 However, the benefits of corticosteroid injection in the management of RLP and PLP remain to be defined. On the basis of the above suggested mechanism and potential benefits of adding steroid, we have used the combination of Lidocaine and Depomedrol as a control arm to be compared with Botox injection in this study. The significant improvements of RLP and pain tolerance were observed in amputees treated with Lidocaine/Depomedrol injection, suggesting this combination regimen is a treatment option in amputees with RLP who failed in conservative (noninterventional) treatments. The improvement of RLP and pain tolerance lasted for approximately 6 months. This is clearly longer than Lidocaine injection alone as the pharmacologic effect of lidocaine usually last for no more than 1 hour. One possible explanation, although many exist, is that inflammatory or neuro-inflammatory mechanism may be involved in the development of RLP. Botox has been used to treat the spasticity and other hypertonic muscular diseases for years by selectively preventing the release of acetylcholine at the nerve-muscle junction. Recently, Botox has been explored as a tool to alleviate pain, including RLP and PLP. 21, 23 Several studies [22] [23] [24] reported that intramuscular and/or cutaneous injections of Botox produced significant relief in RLP and PLP. Our data are congruent with these studies and showed a significant reduction in RLP in the study amputees. The effect of RLP relief was significant (>50%) and seemed to be more effective in the first 3 months after Botox injection, which was still effective up to 6-month time point of visit. It is well known that the antispasticity effect of Botox usually lasts for about 3 months via inhibition on the synaptic transmission of acetylcholine at the motor end-plate 13, 28, 29 before the compensatory nerve sprouting and regeneration process completes. But the effect of pain relief may last longer than 3 months as observed in our study and others. 21 The underlying mechanism of Botox in promoting pain relief remains a subject of investigation. More than 3month lasting effect observed by us and others 21 may suggest mechanisms other than the cholinergic participated in the relief of RLP. Botox may affect both cholinergic fibers and noncholinergic nociceptive sensory fibers. Pain relief after Botox injection might be due to reduced myofascial pain related to muscle spasm/tightness evidenced by focal muscle fasciculation as Botox injected directly into the muscular structures under electromyography guidance. It may also minimize ectopic discharges from neuroma, and decreased release of nociceptors in peripheral pain pathways 15, [30] [31] [32] [33] when Botox was administered at the neuroma site or near the nociceptive structures either intramuscularly or cutaneously and subcutaneously. Animal models suggest that Botox reduces the release of substance P, glutamate, c-Fos gene expression, 30 and calcitonin generelated peptide peripherally, 15, 34 and at the dorsal root ganglion. 15, 30 We speculate that both anticholinergic effect and direct inhibition of sensory neurons may explain the effect of pain relief in our amputees. 
